Completed PHASE3 INTERVENTIONAL 2-arm NCT02432885

Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial

Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - Angiotensin-Converting-Enzyme (ACE) Inhibitor Therapy

Sponsor: Federal University of Minas Gerais

Conditions Muscular Dystrophies Myocardial Fibrosis

Interventions Enalapril

Updated 5 times since 2017 Last updated: May 1, 2015 Started: Jun 30, 2009 Primary completion: Jun 30, 2012 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02432885, this PHASE3 trial focuses on Muscular Dystrophies and Myocardial Fibrosis and remains completed. Sponsored by Federal University of Minas Gerais, it has been updated 5 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Federal University of Minas Gerais
InCor Heart Institute
University of Sao Paulo

Data source: InCor Heart Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.